Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Symptomatic Treatment of MS - European Multiple Sclerosis Platform
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97: 1030-1034.<br />
218. Sabatowski R, Galvez R, Cherry DA, Jacquot F, Vincent E, Maisonobe P, Versavel M; 1008-045 Study<br />
Group (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients<br />
with post-herpetic neuralgia: results <strong>of</strong> a randomised, placebo-controlled clinical trial. Pain<br />
109:26-35<br />
219. Sailer M, Heinze HJ, Schoenfeld MA, Hauser U, Smid HG (2000) Amantadine influences cognitive<br />
processing in patients with multiple sclerosis. Pharmacopsychiatry 3:28-37<br />
220. Sakurai M, Kanazawa I (1999) Positive symptoms in multiple sclerosis: their treatment with<br />
sodium channel blockers, lidocain and mexiletine. J Neurol Sci 162:162-168<br />
221. Samar VJ, Metz DE (1988) Criterion validity <strong>of</strong> speech intelligibility rating scale procedures for the<br />
hearing-impaired population. J Speech Hear Res 31:307-316<br />
222. Sanders DS, Carter MJ, D’Silva J, James G, Bolton RP, Willemse PJ, Bardhan KD (2002) Percutaneous<br />
endoscopic gastrostomy: a prospective audit <strong>of</strong> the impact <strong>of</strong> guidelines in two district general<br />
hospitals in the United Kingdom. Am J Gastroenterol 97:2239-2245<br />
223. Sapir S, Pawlas A, Ramig LO, Seeley E, Fox C, Corboy J (2001) Effects in intensive phonatory-respiratory<br />
treatment (LSVT) on voice in two individuals with multiple sclerosis. J Med Speech Lang<br />
Pathol 9:141-151<br />
224. Sauerwein D (2002) Urinary tract infection in patients with neurogenic bladder dysfunction. Int J<br />
Antimicrob Agents 19:592-597<br />
225. Sawa GM, Paty DW (1979) The use <strong>of</strong> bacl<strong>of</strong>en in treatment <strong>of</strong> spasticity in multiple sclerosis. Can<br />
J Neurol Sci 6:351-354<br />
226. Schiffer RB, Wineman NM (1990) Antidepressant pharmacotherapy <strong>of</strong> depression associated with<br />
multiple sclerosis. Am J Psychiatry 147:1493-1497<br />
227. Schüler P, Seibel K, Chevts V, Schaffler K (2002) Analgetische Wirkung des selektiven Noradrenalin-Wiederaufnahme-Hemmers<br />
Reboxetin. Nervenarzt 73:149-154<br />
228. Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weiss C, Knispel HH (2006) Efficacy <strong>of</strong><br />
botulinum-A toxin bladder injections fort he treatment <strong>of</strong> neurogenic detrusor overactivity in<br />
multiple sclerosis patients. An objective and subjective analysis. Neurourol Urodyn 25: 110-115<br />
229. Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K et al. (2005) Botulinum toxin<br />
type a is a safe and effective treatment for neurogenic urinary incontinence: results <strong>of</strong> a single<br />
treatment, randomized, placebo controlled 6-month study. J Urol 174:196–200.<br />
230. Schurr MJ, Ebner KA, Maser AL, Sperling KB, Helgerson RB, Harms B (1999) Formal swallowing<br />
evaluation and therapy after traumatic brain injury improves dysphagia outcomes. J Trauma<br />
46:817-821<br />
231. Schwartz CE (1999) Teaching coping skills enhances quality <strong>of</strong> life more than peer support: results<br />
<strong>of</strong> a randomized trial with multiple sclerosis patients. Health Psychol 18:211-220<br />
E<strong>MS</strong>P, <strong>Symptomatic</strong> <strong>Treatment</strong> <strong>of</strong> <strong>Multiple</strong> <strong>Sclerosis</strong>, December 2006 - revised in April 2008 56
Change language